Diana Li

Co-Head of Life Science Practice Group at Fangda Partners

Speaker

Ms. Diana Li is the co-head of the firm’s life sciences and healthcare practice. Diana’s work spans the full spectrum of the sector - from biotech, pharmaceuticals, and medical devices to healthcare services - advising both leading investment funds and innovative companies on complex transactions. Diana has been consistently recognized by Legal 500, AsiaLaw, and Chambers & Partners from 2020 to 2026 as a leading lawyer in life sciences and healthcare sector.

Her practice spans cross-border licensing and collaboration deals for multinational pharmaceutical companies and emerging biotechs in both license-in and license-out arrangements across China, the U.S., Europe, and Asia, as well as private equity and M&A transactions advising institutional investors on strategic investments in high-growth life science companies. She has also advised on Hong Kong and U.S. listings, privatizations, and provides regulatory and compliance counsel to global industry leaders and emerging innovators on legal developments in China and internationally.